-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The European Urological Association (EAU) 2021 Virtual Meeting of Oncology Urology (ESOU) presented a must-read paper on urological oncology from 2020, discussing important papers related to prostate cancer.
first paper published in the New England Journal of Medicine, "MRI Targeting, Systematic and Joint Biopsies for Prostate Cancer."
1 paper assessed whether magnetic resonance imaging (MRI) for biopsies could reduce MRI visible lesions in men with incorrect classification of prostate cancer.
a total of 2,103 men with MRI visible prostate lesions received MRI targeted and systematic biopsies, the main results of which were cancer, according to the hierarchy.
addition, upgrades and downgrades of the whole tissue pathology analysis from biopsies to surgical specimens were recorded in men who subsequently underwent prostate cancer treatment.
the authors found that 1,312 (62.4%) of cancers were diagnosed in combination, while 404 men (19.2%) received treatment for prostate cancer.
the cancer detection rate of MRI-targeted biopsies was significantly lower than that of systematic biopsies, for stage 1 cancers, and significantly higher in groups 3 to 5 (p .lt;0).
）。
combined biopsy resulted in 208 more men (9.9 per cent) being diagnosed with cancer than men using either method alone, and upgraded to the senior group of 458 men (21.8 per cent).
, however, 8.8% of clinically important cancers (≥3 groups) would be misclassified if only MRI target biopsies were performed (see: NEJM:...) MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here
